Related Experiment Video
Updated: Aug 14, 2026

Visualization of Bacterial Resistance using Fluorescent Antibiotic Probes
Published on: March 2, 2020
Dihydrofolate reductase inhibitors as antibacterial agents
Stephen Hawser1, Sergio Lociuro, Khalid Islam
1Arpida Ltd., Dammstrasse 36, 4142 Münchenstein, Switzerland. shawser@arpida.ch
Abstract:
Although only a few DHFR inhibitors have progressed as antibiotics to the market there is much renewed interest in the discovery and development of new generation DHFR inhibitors as antibacterial agents. This article describes the success in exploiting DHFR as a drugable target as exemplified by trimethoprim (TMP) and the development of several new diaminopyrimidines. Iclaprim, a recent example of a novel diaminopyrimidine currently in Phase III clinical trials, is also described together with several examples of anti-DHFR antibacterial compounds in pre-clinical development.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Antiprotozoal Agents
Anthelminthic Agents
Inhibitors of Bacterial Protein Synthesis
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
